On December 15, 2015, the Court issued an order denying Defendants’ motion to dismiss in part, in the action captioned In re Enzymotec Ltd. Securities Litigation, Civil Action No. 2:14-cv-5556 (D.N.J.). Saxena White is serving as Co-Lead Counsel on behalf of three individual investors in the action. The Court found that Plaintiffs’ core allegations concerning Enzymotec’s financial guidance, its sales of InFat in China, and its knowledge of impending Chinese regulatory changes were properly pled. The Court concluded that “Lead Plaintiffs have set forth sufficient allegations of materially false and misleading statements with respect to guidance, forecasts, and predictions to survive the Motion to Dismiss with respect to InFat”; that the “particularized allegations before this Court of motive viewed in the context of the Amended Complaint as a whole are compelling” and “a reasonable person would deem the inference of scienter at least as strong as any opposing inference”; and that Lead Plaintiffs properly pled their Securities Act claims. The action has now progressed into the discovery phase of litigation.